Investigating the Use of TaVNS to Treat Insomnia in Individuals with Breast Cancer (taVNS-insomnia-BC)

Description

In the present study, the investigators aim to investigate feasibility of utilizing noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to address insomnia in patients with stage I-IV breast cancer.

Conditions

Breast Cancer, Insomnia

Talk to us

Study Overview

On this page

Study Details

Study overview

In the present study, the investigators aim to investigate feasibility of utilizing noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to address insomnia in patients with stage I-IV breast cancer.

Investigating the Feasibility of Using TaVNS to Treat Insomnia in Individuals with Stage I-IV Breast Cancer

Investigating the Use of TaVNS to Treat Insomnia in Individuals with Breast Cancer (taVNS-insomnia-BC)

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Birmingham

UAB Lakeshore Collaborative (WHARF), Birmingham, Alabama, United States, 35209

Birmingham

UAB Spain Rehabilitation Center, Birmingham, Alabama, United States, 35233

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. at least 18 years of age
  • 2. diagnosed stage I-IV breast cancer
  • 3. self-reported difficulty falling asleep, staying asleep, or waking up too early, for at least three nights per week for a duration of at least three months
  • 4. beginning or worsening of sleep disturbance since cancer diagnosis (did your sleep problems begin or get worse with the diagnosis of cancer or with chemotherapy?)
  • 5. English-speaking
  • 1. Are using a daily sleep aid except melatonin (use of a sleep aid as needed will be permitted, and use will be noted).
  • 2. have a history of severe mental illness
  • 3. have an implanted medical device of any type
  • 4. have a history of seizures
  • 5. have peripheral neuropathy including temporal mandibular disorders and Bells Palsy
  • 6. have vasovagal syncope
  • 7. have moderate to severe cognitive impairment
  • 8. have \<6 months to live as determined by the physician

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Alabama at Birmingham,

Alexandra Evancho, DPT, PRINCIPAL_INVESTIGATOR, The University of Alabama at Birmingham

Study Record Dates

2025-12-31